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Abstract.  The interaction of lymphocyte function- 
associated antigen-1  (LFA-1) with its ligands mediates 
multiple cell adhesion processes of capital importance 
during  immune responses. We have obtained three 
anti-ICAM-3  mAbs which recognize two different epi- 
topes (A and B) on the intercellular adhesion 
molecule-3 (ICAM-3) as demonstrated by sequential 
immunoprecipitation  and cross-competitive mAb- 
binding experiments.  Immunoatfinity purified ICAM-3- 
coated surfaces were able to support T lymphoblast 
attachment upon cell stimulation with both phorbol es- 
ters and cross-linked CD3, as well as by mAb engage- 
ment of the LFA-1 molecule with the activating anti- 
LFA-1 NKI-L16 mAb.  T  cell adhesion to purified 
ICAM-3 was completely inhibited by cell pretreatment 
with mAbs to the LFA-lot (CDlla) or the LFA-~ 
(CD18) integrin chains.  Anti-ICAM-3 mAbs specific 
for epitope A, but not those specific for epitope B, 
were able to trigger T lymphoblast homotypic aggre- 
gation.  ICAM-3-mediated cell aggregation  was depen- 
dent on the LFA-1/ICAM-1  pathway as demonstrated 
by blocking experiments with mAbs specific for the 
LFA-1 and ICAM-1 molecules. Furthermore,  im- 
munofluorescence studies on ICAM-3-induced cell ag- 
gregates revealed that both LFA-I  and ICAM-1  were 
mainly located at intercellular boundaries.  ICAM-3 
was located at cellular uropods, which in small ag- 
gregates appeared to be implicated in cell-cell con- 
tacts, whereas in large aggregates it appeared to be ex- 
cluded from cell-cell contact areas.  Experiments of T 
cell adhesion to a chimeric ICAM-1-Fc molecule re- 
vealed that the proaggregatory anti-ICAM-3 HP2/19 
mAb was able to increase T lymphoblast attachment 
to ICAM-1,  suggesting that T cell aggregation induced 
by this rnAb could be mediated by increasing  the 
avidity of LFA-1 for ICAM-1.  Moreover, the HP2/19 
mAb was costimulatory with anti-CD3 mAb for T 
lymphocyte proliferation,  indicating that enhancement 
of T cell activation could be involved in ICAM-3- 
mediated adhesive phenomena.  Altogether,  our results 
indicate that ICAM-3 has a regulatory role on the 
LFA-1/ICAM-1  pathway of intercellular adhesion. 
fine regulation  of intercellular  interactions  is essential 
for the normal function of the immune system.  The 
interaction  of the  leukocyte  integrin  lymphocyte 
function-associated antigen-1  (LFA-I,'  CDlla/CD18)  with 
its ligands is one of the several regulated pathways involved 
in leukocyte cell interactions  (Springer,  1990).  Two mem- 
bers of the immunoglobulin  superfamily,  the intercellular 
adhesion moleculed (ICAM-1) and -2 (ICAM-2), act as coun- 
ter-receptors for the LFA-1 integrin  (Marlin  and Springer, 
1987; Staunton et al., 1989). ICAM-1 is an inducible mole- 
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intercellular adhesion molecule; LFA-1, lymphocyte function-associated an- 
tigen  1. 
cule which is highly expressed on the cell surface of cyto- 
kine-activated  endothelial  and epithelial  cells, as well as on 
macrophages  and  activated  lymphocytes  (Dustin  et  al., 
1986).  In contrast, ICAM-2 is constitutively  expressed on 
vascular endothelium  and most leukocytes (De FougeroUes 
et al.,  1991; Nortamo  et al.,  1991a,b).  Recently,  a  third 
counter-receptor for LFA-1 (ICAM-3) has been identified by 
the ability of the CBR-IC3/1 mAb to inhibit,  in conjunction 
with anti-ICAM-1 and anti-ICAM-2 mAb, cell attachment to 
purified LFA-1 (De Fougerolles and Springer,  1992). Clon- 
ing and sequencing  studies  revealed  that ICAM-3 also be- 
longs to the immunoglobulin  superfamily  (De Fougerolles et 
al.,  1993; Fawcett et al.,  1992; Vazeux et al.,  1992).  In- 
terestingly, ICAM-3 is absent on endothelial cells, and its ex- 
pression appears to be restricted to the leukocyte lineage, 
being  highly  expressed by monocytes,  lymphocytes, and 
neutrophils  (De Fougerolles and Springer,  1992). Whereas 
© The Rockefeller University Press, 0021-9525/93/11/1007/10 $2.00 
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different immune processes,  no functional role has  SO far 
been reported for ICAM-3. 
We here describe the generation and epitope mapping of 
three novel anti-ICAM-3 mAb. We have used these rnAb to 
purify ICAM-3,  and  to  study the  regulation of leukocyte 
adhesion  to the purified molecule.  We have also found a 
regulatory role of ICAM-3 on the LFA-1/ICAM-1  adhesion 
pathway. 
Materials and Methods 
Monoclonal Antibodies 
Anti-ICAM-3  HP2/19,  TP1/24,  and  TPI/25;  anti-LFA-lc~ TP1/40  and 
TP1/32;  and anti-LFA/~ Lia 3/2  mAb were  obtained from fusions with 
splenocytes  from mice immunized with the human leukemic JM cell line 
(HP2/19 mAb), human T-lymphocytes activated for 24 h with a combination 
of PMA and anti-CD3 mAb (TP series), or the promyelomonocytic  U937 
cell line (Lia 3/2 mAb). The anti-ICAM-3 CBR-IC3/1, anti-CDlla TS1/ll 
and NKI-L16, anti-CD18 TSI/18, anti-ICAM-1 RRI/1 and LB-2, anti-CD29 
Lia  1/2 and TS2/16, anti-CIM5 D3/9,  anti-CD43 TP1/36, anti-HLA-A,B 
W6/32,  and anti-CD3  SPV-T3b mAb have been described (De Fougerolles 
and Springer,  1992; S~nchez-Madrid et al., 1983; Keizer et al., 1988; Roth- 
lein et al., 1986; Clark et al., 1986; Campanere et al., 1991, 1992; Hemler 
et al., 1984; Pulido et al., 1988; Barnstable et al., 1978; Spits et al., 1985). 
The anti-CD31  TPI/15 mAb was generated in our laboratory,  and will be 
described elsewhere.  For cell adhesion and aggregation experiments as well 
as  for  mAb radiolabeling, mAbs were  purified  from ascites  fluid  with 
protein A  coupled to  Sepharose (Pharmacia Fine Chemicals,  Uppsala, 
Sweden).  F(ab')2  fragment of HP2/19 mAb was  prepared as previously 
reported (Parham et al.,  1982).  P3X63 myeloma culture supernatant was 
used as negative control. 
Cells and Cell Lines 
Nentrophils were  isolated  from fresh human blood by  Ficoll-Hypaque 
density gradient centrifugation (Pharmacia LKB Biotechnology,  Piscata- 
way, NJ), followed by sedimentation at 1 g in dextran (Sigma Chem. Co., 
St. Louis, MO) at room temperature. The neutrophil-enriched  fraction was 
further purified by hypotonic lysis of erythrocytes, giving a purity higher 
than 98%. 
T lymphoblasts were prepared from peripheral blood mononuclear cells 
by treatment with phytohaemagglntinin  (0.5 %; Pharmacia LKB Biotechnol- 
ogy) for 48 h. Cells were washed and cultured in RPMI 1640 (Flow Labs, 
Irvine, Scotland)  containing 10%  FCS (Flow  Labs) and 20 U/ml IL-2. 
7-12 d T lymphoblasts were typically used in all the experiments.  T lym- 
phoblasts and T cell clones have been extensively used to study both LFA-1- 
mediated cell adhesion and T cell activation (Cantrell and Smith, 1984; Van 
Kooyk et al., 1991; Dransfield et al., 1992). The Jurkat T cell line was main- 
tained in RPMI 1640 plus 10% FCS. 
Purification of  lCAM-3 by mAb 
A~nity Chromatography 
ICAM-3  was  purified  from detergent lysates  of human neutrophils by 
affinity chromatography using the anti-ICAM-3  TP1/24 mAb coupled to 
CN'Br-activated  Sepharose CL-4B (Pharmacia LKB Biotechnology)  at 2 
mg/ml. All chromatography steps were performed at 4°C, and all buffers 
contained 5 mM iodoacetamide,  1 mM PMSE 0.2 U/ml aprotinin, and 
0.025 % NAN3. Human neutrophils were lysed in a 20 mM Tris-HCl, pH 
8.0, 0.5 % Triton X-100 (TX-100) buffer. Lysates were centrifuged at 2,500 g 
for 60 rain and the supernatant was passed in series through columns of 
CNBr-activated  glycine-quenched  Sepharose  CL-4B  and  anti-ICAM-3 
TP1/24-Sepharose  CL-4B. The TP1/24-Sepharose  column was washed with 
50 mM ethanolamine, pH 10, 0.5 M NaC1, 1% n-octyl-/~-D-glucopyranoside 
(ootylglucoside,  OG). Then, proteins bound to the column were eluted with 
50 mM ethanolamine, pH 11, 0.5 M NaCI,  1% octylglucoside.  Eluates were 
immediately neutralized with 2 M Tris-HC1 pH 6.7. Fractions containing 
the eluted ICAM-3 were identified  by SDS-7%  PAGE, and proteins were 
visualized by silver staining (Pulido et al.,  1988).  Fractions containing 
ICAM-3  were pooled and concentrated ,x,30-fold by using Centricon-100 
microconcentrators (Amicon, Danvers, MA), and reanaiyzed by SDS-7% 
PAGE. As estimated by silver staining and comparison to standard proteins, 
ICAM-3  was concentrated up to 40 #g/ml. 
Radiolabeling and Cross-Competitive mAb 
Cell-Binding Assays 
Both purified ICAM-3 and anti-ICAM-3 mAb, as well as neutrophils, were 
radioiodinated in solution with chlorogl~oluril (IODO-GEN,  Pierce Chem. 
Co., Rockford,  IL), as described (S~lnchez-Madrid et al.,  1983; Pulido et 
al., 1991). For cross-competitive  mAb cell-binding  assays, Jurkat cells were 
preincubated in RPMI  1640  (5  x  106/ml) with an excess  of unlabeled 
mAb for 30 min at 4°C.  Then,  125I-labeled mAb (2  x  103 cpm)  were 
added and incubated for another 30 min at 4"C. Afterwards, unbound radio- 
activity was removed by washing with RPMI, and cell-bound radioactivity 
was measured in a gamma counter. 
Figure 1.  Characterization of three novel anti-ICAM-3 mAb.  (A) 
125I-labeled cell lysates from neutrophils were immunoprecipitated 
with the following mAbs: control P3X63  (lane 1),  anti-ICAM-3 
CBR-IC3/I (lane 2), HP2/19 (lane 3), TP1/24 (lane 4), and TPI/25 
(lane 5), anti-CD43 TP1/36 (lane 6), anti-LFA-1 TPI/40 (lane 7), 
and anti-LFA-/~ Lia 3/2 (lane 8); M, M~ markers (200,  100, 95, 69, 
46, and 30 kD). (B) 125I-labeled neutrophil lysates were precleared 
with the anti-CD31 TPI/15 mAb (lanes 1-5)or with the anti-ICAM-3 
TP1/24 mAb (lanes 6-10), and then were immunoprecipitated with 
the anti-CD31 TP1/15 (lanes 1 and 6), anti-ICAM-3 TP1/24 (lanes 
2 and 7), TP1/25 (lanes 3 and 8), CBR-IC3/1 (lanes 4 and 9), and 
HP2/19 (lanes 5 and I0) mAbs. Immune complexes were isolated, 
and reduced samples were subjected to SDS-10% PAGE and auto- 
radiography. 
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Radiolabeled neutrophils were lysed in lysis buffer (PBS, pH 7.4 containing 
1% Triton X-100,  1% hemoglobin and  1 mM PMSF). Equal amounts of 
125I-labeled proteins (either from neutrophil lysates or purified ICAM-3) 
were mixed with 100/~1 of mAb-containing culture supernatant. To isolate 
immune complexes, 100/zl of 187.1 anti-mouse kappa chain mAb followed 
by 30/zl protein A coupled to Sepharose were added. For sequential immu- 
noprecipitation, lysates were precleared by incubation with the first mAb 
coupled to CNBr-Sepharose, followed by centrifugation to pellet the im- 
mune complexes. Then, the supernatants were precipitated with the second 
mAb. Immunoprecipitates were processed as described (S~tnchez-Madrid et 
ai.,  1983)  and analyzed by SDS-PAGE and autoradiography. 
Cell Adhesion Assays 
Adhesion assays were essentially performed as previously described (Ar- 
royo et al.,  1992).  Briefly,  40 #l/well of either purified ICAM-3  (0.1-4 
/~g/ml)  or human serum albumin  (HSA;  100  /zg/ml)  in TSM  (washing 
buffer; 25 mM Tris-HCl, pH 8.0, 150 mM NaC1, 2 mM MgCI2,  0.1% oc- 
tylglucoside), were used to coat 96-well microtiter EIA II-Linbro plates 
(Costar Corp., Cambridge, MA) for 2 h at 37°C, and then saturated with 
washing buffer containing 1% HSA for 30 rain at 37°C. Thereafter, plates 
were washed with washing buffer, and 2-3  ×  105 cells/well in 100 ~1 were 
added and centrifuged for 5 min at 10 g before incubation at 37°C for 10-20 
min. Cell adhesion to a chimeric recombinant soluble ICAM-1-Fc (Berendt 
et al., 1992) (40 #l/well at 10 #g/ml) was performed in a similar way except 
that 0.1% octylglucoside was excluded from all the steps. To quantify cell 
attachment, the plate was washed with washing buffer, cells were fixed with 
a mixture of acetone/methanol 1:1, and dyed with violet crystal 0.5 %. Then, 
absorbance  at  540  run  was  measured  in  an  ELISA  detector  (LP400, 
Kallestad, Chaska, MN) and optical density was found to be a linear func- 
tion of number of cells by a calibration curve (optical density vs number 
of cells). Total cellular input was calculated by spinning wells with original 
number of cell aliquots, staining, and measuring optical density. 
Aggregation Assays 
Homotypic cell aggregation was performed as previously described (Cam- 
panero et al., 1990).  Briefly, cells were incubated in flat-bottomed, 96-well 
microfiter plates (Costar Corp.) in duplicate at 1.5 x  106/ml in a final vol- 
ume of 100 tzl of complete medium, mAbs were added at 1 ~g/ml and cells 
were allowed to settle in a cell incubator at 37°C and 5% CO2 atmosphere. 
Aggregation was then determined at different periods of time by direct visu- 
alization of  the plate with an inverted microscope and counting the free cells 
of at least five randomly chosen areas of 0.025 mm  2, delimited by a special 
mask consisting of squares, under the plate. Results were expressed as per- 
cent of aggregated cells. 
Immunofluorescence 
T lymphoblasts were incubated in flat-bottomed, 24-well microtiter plates 
(Costar Corp.) at 4  x  106 cells/ml in a final volume of 500 #1 of complete 
medium, mAbs or their F(ab')2 fragments were added at a final concentra- 
tion of 1/zg/ml and cells were allowed to settle in a cell incubator at 37°C 
and 5% CO2 atmosphere; after either 1 (small cell aggregates) or 2 h (large 
cell aggregates), cells were fixed with 3.7 % formaldehyde in PBS for 10 min 
at room temperature and rinsed in TBS (TBS:  50 mM Tris-HCl, pH 7.6, 
150 mM NaC1,  0.1% NAN3). To directly visualize the mAb that induced 
the process of aggregation, ceils were stained with a  1:50 dilution of the 
FITC-labeled rabbit F(ab')2 anti-mouse IgG (Pierce) as a secondary anti- 
body. To visualize other membrane proteins, cell aggregation was induced 
with the F(ab'h fragment of anti-ICAM-3 HP2/19 mAb (1 eg/ml) and after 
fixation, the cells were incubated with another mAb followed by washing 
and labeling with a  1:50 dilution of the Frrc-conjugated goat anti-mouse 
Fc fragment of IgG (Sigma Chem. Co.). The cells were observed using a 
Nikon Labopbot-2 photomicroscope with a 60  x  oil immersion objective 
and photographed on TMAX 400 film (Kodak) processed to 800-1600 ASA 
with TMAX developer (Eastman Kodak Co., Rochester, NY). 
Proliferation Assays 
50/~1 F(ab')2 sheep anti-mouse IgG at Z5 ttg/rnl in 20 mM Tris-HC1,  pH 
8.0,  was placed in each well of a  96-well flat-bottomed microtiter plate 
(Costar Corp.) overnight at 4°C. After washing twice with PBS, the indi- 
cated amounts of mAb directed against different lymphocyte surface anti- 
gens were placed in each well and incubated at 37°C for an additional hour. 
Then, wells were washed twice with RPM11640. Peripheral blood mononu- 
clear cells were depleted of monocytes by adherence to plastic plates at 
37°C for >3 h. 50,000 cells in 200 t~l of RPMI 1640-10% FCS were added 
to each well and cultured in triplicate for 3 d. Cell proliferation was esti- 
mated by [3H]dThd  (New England Nuclear, Boston, MA) incorporation 
during the last 16 h of culture. Cells were harvested and the radioactivity 
measured in a liquid scintillation counter. 
Results 
Characterization  of the Specificity of Three Novel 
Anti-ICAM-3 mAbs 
Three mAbs (HP2/19,  raised against  the JM leukemic cell 
line; and TP1/24 and TP1/25, raised against human activated 
T lymphocytes) were selected. These mAbs immunoprecipi- 
tared  from  ~2~I-cell surface  labeled  human  neutrophils  a 
135-kD polypepfide (Fig.  1 A, lanes 3-5) that resembled the 
immunoprecipitafion  pattern produced by the recently de- 
scribed anti-ICAM-3  CBR-IC3/1 mAb (De Fougerolles  and 
Springer,  1992) (Fig.  1 A, lane 2). To ascertain the specific- 
ity of these three novel mAbs, sequential  immunoprecipita- 
tion experiments  were carried out in conjunction  with the 
anti-ICAM-3 CBR-IC3/1 mAb. The TP1/24 mAb precleared 
Table L  Topographic Epitopes on the ICAM-3 Molecule 
~2~I-labeled mAb 
Unlabeled  mAb  Specificity  CBR-IC3/1  HP2/19  TP1/24 
Induction  of 
Epitope  cell aggregation ~+) 
Bound radioactivity  e) 
CBR-IC3/1  ICAM-3  1536  3238  17152 
HP2/19  "  1552  2862  19345 
TP1/24  "  6434  26614  3718 
TPl/25  "  6188  26850  3531 
Control mAb 
TS1/11  LFA-1  6642  31723  23611 
P3X63  -  6694  30769  19289 
A  + 
A  + 
B 
B 
* Binding of nSl-labeled purified mAb (2  x  I0  5 cpm) to Jurkat  cells was inhibited with an excess of unlabeled competitor mAb, as described under Materials 
and Methods. Bound radioactivity  was measured  and data (clam) are expressed as mean of two separate experiments. 
* Cell aggregation  of T lymphoblasts was quantified as described under Materials  and Methods. +  and -  mean, respectively,  over 50% and below 20%  of cell 
aggregation. 
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noatfinity  purified  ICAM-3.  (A) 
ICAM-3 from human neutrophils 
was  purified  by  immunoaflinity 
chromatography. Samples of flow 
through (lane 1), pH 10 washing 
(lane 2), and pH 11 eluates (lanes 
3-5) containing purified ICAM-3, 
were  electrophoresed  under  re- 
ducing conditions  on an SDS-7 % 
PAGE and  visualized  by  silver 
staining.  (B)  Purified  ICAM-3 
was  radiolabeled  and  immuno- 
precipitated  with  the  following 
mAbs:  anti-LFA-1  TSI/ll  (lane 
1 ), anti-ICAM-3 TP1/25 (lane 2), 
and  TPI/24  (lane  3)  mAb.  Im- 
mune  complexes  were  isolated, 
and  reduced  samples  were  sub- 
jected to SDS-7%  PAGE  and au- 
toradiography. 
the antigen recognized by either TP1/25 and HP2/19 mAb, 
as well as that precipitated by the anti-ICAM-3 CBR-IC3/1 
mAb, but not that recognized by the anti-CD31 TP1/15 mAb, 
included as a control (Fig.  1 B, lanes 6--10).  Conversely, the 
anti-CD31  TP1/15 mAb did not preclear the antigen recog- 
nized by CBR-IC3/1, HP2/19, TP1/24, or TP1/25 mAb (Fig. 
1 B,  lanes  1-5).  Thus,  these  results  demonstrate  that  the 
novel  HP2/19,  TP1/24,  and  TP1/25  mAb  recognize  the 
ICAM-3 molecule. 
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Figure 3.  Regulated  lymphocyte adhesion  to purified  ICAM-3. (A) 40 #l/well of ICAM-3 (0.4 #g/ml), ICAM-I-Fc (10 #g/ml), and HSA 
(100 #g/ml) were used to coat 96-well microtiter plates.  T lymphoblasts were pretreated  for 30 min at 4°C with the following  stimuli: 
RPMI (n), 5 ng/ml PMA (u),  10 #g/ml anti-CD3 T3h cross-linked  by using 10 #g/ml sheep anti-mouse IgG ([]), 1:50 dilution  of culture 
supernatant from the anti-LFA-1 NKI-L16 mAb ([]),  and  10 #g/nil of the anti-VLA/31 Lia 1/2 mAb (®). Adhesion was quantified  after 
10 min of incubation at 37°C.  Arithmetic mean and SD of duplicate  wells is shown.  Data are representative  of three experiments.  (B) 
Dose-dependence of cell  adhesion of purified  ICAM-3.  40 #l/well of ICAM-3 at doses ranging from 0.1 to 4 #g/ml were used to coat 
96-well microtiter plates.  T lymphoblasts were stimulated  with either 5 ng/ml PMA (triangles) or RPMI (circle). Data are representative 
of two experiments.  Cell adhesion to HSA was always lower than 5 %. 
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and labeled anti-ICAM-3 mAb (Table I).  The HP2/19 and 
CBR-IC3/1  mAbs cross-blocked each other, but were not 
competed by  the  TP1/24  and  TP1/25  mAbs.  Conversely, 
TP1/24  mAb  was  competed by  TP1/25  mAb,  but not by 
HP2/19 and  CBR-IC3/1  mAbs.  Thus,  two different topo- 
graphic epitopes can be defined on the ICAM-3 molecule: 
epitope A, recognized by HP2/19 and CBR-IC3/1 mAb, and 
epitope B, recognized by TP1/24 and TP1/25 mAbs. 
Regulation of T Cell Binding to 
lmmunopurified ICAM-3 
ICAM-3 was purified by mAb immunoaflinity chromatogra- 
phy from human neutrophils which exhibit a high membrane 
expression of ICAM-3 (De Fougerolles and Springer, 1992). 
Neutrophils were lysed with the detergent Triton X-I00, and 
ICAM-3 was purified from the lysate by binding to a TP1/24 
inAb Sepharose column. Immunopurified ICAM-3 appeared 
as a broad band around 135 kD upon SDS-PAGE (Fig. 2 A). 
The purified molecule was radiolabeled and subjected to im- 
munoprecipitation with different mAbs. Both anti-ICAM-3 
TP1/24 and TP1/25, but not the anti-LFA-lc~  TS1/ll mAb, 
were able to precipitate the 135-kD purified ICAM-3 protein 
(Fig. 2 B) consistent with previous observations from immu- 
noprecipitation experiments (Fig.  1). 
To determine  whether  ICAM-3  could  mediate  cellular 
adhesion, a solution containing the purified glycoprotein was 
used to coat plastic dishes on which cell binding could be 
analyzed.  When untreated T  lymphoblasts were added to 
ICAM-3 coated wells, a small percentage of cells (+t0%) 
was specifically bound (Fig.  3 A). However, phorbol ester 
treatment of T lymphoblasts greatly enhanced cell binding 
to ICAM-3 (Fig. 3, A and B). 
To  test  whether  other  stimuli,  besides  phorbol  esters, 
could be able to enhance cell binding to ICAM-3, T lympho- 
blasts were treated with different mAbs against functionally 
relevant molecules on T cells. Engagement of either CD3- 
TcR by cross-linked anti-CD3 mAb, or the LFA-1 integrin by 
the proaggregatory and activating anti-LFA-1 NK1-L16 mAb 
(Keizer et al.,  1988) greatly enhanced T lymphoblast adhe- 
sion to purified ICAM-3 (Fig. 3 A). In contrast, cell treat- 
ment with the proaggregatory anti-VLAB1  (CD29) Lia 1/2 
nlAb (Campanero et al.,  1992) did not modify cell attach- 
ment to purified ICAM-3 (Fig. 3 A). These results indicate 
that cellular avidity for ICAM-3 can be specifically regulated 
upon cell activation and suggest that the LFA-I integrin can 
be directly involved in this process. A similar profile of cell 
adhesion was obtained with ICAM-l-coated surfaces, while 
no binding was observed with purified HSA (Fig. 3 A). 
A  dose-response curve (Fig.  3 B) showed that,  upon T 
lymphoblast activation with PMA,  significant cell binding 
could be supported with ICAM-3 amounts as low as 10 ng 
per well and reached maximal binding with 20 ng per well. 
Dose dependence of cell adhesion to the purified glycopro- 
tein suggested the specificity of the assay that was further 
confirmed in mAb blocking experiments (see below). 
To determine the direct involvement of the LFA-1 integrin 
in cell binding to purified ICAM-3, inhibition studies with 
specific mAb were carried out. Three different anti-LFAlot 
(CDI la) mAbs (TP1/40, TS1/11, and TP1/32), as well as two 
different anti432 (CD18) mAbs (Lia 3/2 and TS1/18) com- 
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Figure 4. Inhibition of T-cell adhesion to purified ICAM-3 by anti- 
LFA-lc~ and t5 mAb. Unstimulated and PMA-treated (5 ng/ml) T 
lymphoblasts were allowed to bind to either (A) purified ICAM-3- 
(0.4 gg/ml) or (B) ICAM-1-Fc-coated (10 #g/ml) microtiter wells 
in the presence of blocking mAb.  1 #g/ml inhibitor mAbs were 
used to pretreat for 30 rain at 4°C either the cells (anti-LFA-lct, 
anti-LFA-/3, and anti-CD45) or the wells (anti-ICAM-1 and anti- 
ICAM-3). Adhesion was quantified after 10 min of incubation at 
37°C. Arithmetic mean and SD of duplicate wells is shown. Data 
are representative of three experiments. Cell adhesion to HSA was 
always lower than 5 %. 
pletely blocked cell attachment to purified ICAM-3, whereas 
the anti-CD45 D3/9 mAb did not affect cell adhesion (Fig. 
4,  upper panel).  Neither anti-ICAM-1  nor  anti-ICAM-3 
mAb directed to epitope A or B were able to ablate cell bind- 
ing to the ICAM-3 molecule (Fig. 4, upper panel, and data 
not shown). In contrast, the anti-ICAM-1 RR1/1 mAb almost 
completely blocked cell adhesion to recombinant ICAM-1- 
Fc (Fig. 4, lower panel).  The anti-LFAlot and anti-LFA-/3 
mAbs also inhibited cell binding to ICAM-1 (Fig. 4, lower 
panel).  Altogether, these data demonstrate that T lympho- 
blasts are able to specifically interact with purified ICAM-3 
through the LFA-1 integrin. 
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Figure 6. Kinetics of ICAM-3-mediated leukocyte intercellular in- 
teractions. Inhibitory effects of anti-LFA-1 and anti-ICAM-1 mAb. 
T lymphoblasts were pretreated for 30 min at RT with RPMI (o), 
anti-ICAM-3  TP1/24 (zx), anti-ICAM-1 RR1/1 ([]),  anti-LFA-1 
TP1/40 (A), a combination of TPI/24 plus RRI/I (e), and anti- 
VLA/~ TS2/16 mAb  (am), before  the  addition  of anti-ICAM-3 
HP2/19 mAb. Percent of cell aggregation was calculated, as de- 
scribed under Materials and Methods, at different times from the 
beginning of  the assay. Untreated cells showed  always  less than 10% 
of aggregation. Data are representative of five experiments. 
Figure  5. ICAM-3-mediated leukocyte intercellular interactions are 
LFA-1/ICAM-1 dependent. T lymphoblasts were incubated in the 
presence of either anti-ICAM-3 HP2/19 (A) and TP1/24 mAb (B), 
RPMI (G), or anti-LFA-1 NKI-L16 mAbs (H). In C-F, ceils were 
preincubated for 30 min at RT with anti-ICAM-3 TP1/24 (C), anti- 
LFA-I TPI/40 (D), anti-ICAM-I RRI/1 (E), and anti-VLA~ TS2/16 
(F) mAbs before the addition of anti-ICAM-3 HP2/19 mAb. Pho- 
tomicrographs were taken after 2 h from the beginning of the assay. 
Bar, 150/zm. 
LFA-1/ICAM-l-dependent Leukocyte Intercellular 
Interactions Induced through ICAM-3 
To explore the functional role of ICAM-3 in leukocyte inter- 
actions, we have examined the effect of our panel of anti- 
ICAM-3 mAbs in different cell adhesion assays.  Incubation 
of T lymphoblasts in the presence of purified anti-ICAM-3 
epitope A HP2/19 (Table I), as well as with its F(alY)z frag- 
ment,  resulted in the rapid induction of strong homotypic 
cell aggregation (Figs. 5 A and 8). Similar effects were ob- 
served with the CBR-IC3/1 mAb specific for epitope A (Ta- 
ble I). However, the anti-ICAM-3 TP1/24 and TP1/25 mAbs, 
specific for epitope B, did not induce cell clustering (Fig. 5 
B, and Table I). Induction of cell aggregation through the 
ICAM-3 molecule required both an intact metabolism and 
a physiological temperature (data not shown), therefore rul- 
ing out the possibility that intercellular adhesion could be 
due to cell agglutination.  Moreover, cell aggregation trig- 
gered by the anti-ICAM-3 epitope A HP2/19 mAb could be 
blocked by mAb directed against other distinct epitopes on 
the ICAM-3 molecule, as well as by mAb specific for the 
LFA-lo~ (CDlla)  integrin (Fig.  5,  C  and D,  respectively). 
Interestingly,  the  anti-ICAM-1  RR1/1 mAb  also  inhibited 
ICAM-3-induced cell aggregation (Fig. 5 E). By contrast, 
the  anti-VLA/~l  TS2/16 mAb  did  not affect the ICAM-3- 
mediated cell aggregation (Fig. 5 F). T lymphoblast aggre- 
gation triggered by the  anti-LFA-1  NKI-L16 mAb  is  also 
shown for comparison (Fig. 5 H). 
Kinetic expe  "rtments revealed that maximal ICAM-3-induced 
cell aggregation was reached upon 3 h of  T lymphoblast incu- 
bation with the HP2/19 mAb  (Fig.  6).  Cell preincubation 
with mAb against LFA-lt~ (TP1/40), ICAM-1 (RR1/1 and LB- 
2), and ICAM-3 (TP1/24 and TP1/25) partially inhibited cell 
aggregation  triggered  by  the  anti-ICAM-3  HP2/19  mAb, 
whereas the anti-VLA~l TS2/16 mAb showed no inhibitory 
effect at all (Fig. 6, and data not shown). Interestingly, com- 
plete inhibition  of cell  aggregation could be  achieved by 
combination of the  anti-ICAM-1  RR1/1 and  anti-ICAM-3 
TP1/24 mAb (Fig. 6). 
LFA-I and ICAM-I Cluster at Sites of 
CeU-CeU Contacts during ICAM-3 Mediated 
Leukocyte Aggregation 
The results shown above strongly suggested that the LFA- 
1/ICAM-1  interaction could be involved in ICAM-3-medi- 
ated cell aggregation. To further explore the role of the LFA- 
1/ICAM-1 adhesion pathway,  we studied the localization of 
all of these adhesion molecules on ICAM-3-induced cell ag- 
gregates. ICAM-3 displayed a  striking distribution, with a 
The Journal  of Cell Biology,  Volume 123, 1993  1012 Figure 7. Immunofluorescence localization of ICAM-3 in cell ag- 
gregates.  Untreated  T  lymphoblasts  were  fixed and  stained  for 
ICAM-3 (A). T lymphoblast aggregation was induced by using the 
anti-ICAM-3 HP2/19 mAb, and upon cell incubation at 37°C for 
1 (B) or2 h (C), the cells were fixed and stained for ICAM-3. Same 
fields were  photographed  under epifluorescent  (left panels)  and 
bright field (right panels) conditions. Bar, 60 #m. 
stalk-like structure or uropod where ICAM-3 was preferen- 
tiaUy located (Fig. 7, B and C). In contrast, most of mAb- 
untreated cells (over 80 %) showed a  rounded morphology, 
and  ICAM-3  displayed a  more diffuse pattern  of staining 
(Fig.  7  A).  In small aggregates, ceils appeared to contact 
each other through their uropods (Fig. 7 B), whereas in large 
aggregates,  the  uropods  where  ICAM-3  was  located  ap- 
peared to  be excluded  from the areas of cell-cell contact 
(Fig.  7  C). Interestingly, the anti-ICAM-1  RR1/1 mAb, as 
well as the NKI-L16 mAb, which recognizes an activation- 
related epitope on the leukocyte integrin LFA-1 (Van Kooyk 
et al., 1991), preferentially reacted with cell-cell boundaries 
(Fig. 8, A and B). By contrast, the anti-LFA-1  TS1/11 mAb, 
which recognizes a constitutively expressed epitope, as well 
as the anti-VLA/~l TS2/16 mAb showed a more diffuse pat- 
tern of cell surface staining (Fig.  8,  C and D).  Altogether, 
these results suggest that ICAM-3 could be mediating cellu- 
lar events involved in the initiation phase of cell aggregation 
likely by enhancing the avidity of LFA-1 for ICAM-1. 
Increased Cell Binding to ICAM-1 Induced 
through ICAM-3 
To study the regulation of cell binding to ICAM-1, we have 
Figure 8.  Immunofluorescence localization of LFA-1 and ICAM-1 
in cell aggregates. Aggregation of T lymphoblasts was induced for 
2 h at 37°C by using the proaggregatory anti-ICAM-3 HP2/19 mAb. 
Then cells were fixed and stained with either anti-ICAM-1 RR1/1 
(A), anti-LFA-1 NKI-L16 (B) and TS1/ll (C), or anti-VLA/~  TS2/16 
(D) mAbs.  Same fields were photographed  under  epifluorescent 
(left panels) and bright field (right  panels) conditions. Bar, 30 #m. 
used a chimeric recombinant soluble ICAM-1-Fc molecule 
(Berendt et al., 1992). Adhesion of untreated T lymphoblast 
to  plastic  well  coated  with  recombinant  ICAM-1-Fc  was 
completely blocked by both the anti-LFA-1  TP1/40 and the 
anti-ICAM-1 RR1/1 and LB-2 mAb (data not shown),  thus 
indicating that T lymphoblast adhesion is specifically medi- 
ated by the leukocyte integrin LFA-1. Cell pretreatment with 
the  proaggregatory  anti-ICAM-3  HP2/19  mAb  provoked 
about a  twofold increase of T  lymphoblast adhesion to re- 
combinant ICAM-1-Fc, whereas no effect was observed in 
cells treated either with the anti-VLA/~l Lia 1/2 mAb, which 
also induced cell aggregation (Campanero et al.,  1992), or 
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Figure 9. ICAM-3-mediated induction of cell adhesion to ICAM-1. (A) T lymphoblasts were pretreated at 4°C with the following stimuli: 
RPMI, 10/~g/ml of HP2/19, Lia 1/2, TP1/24, and anti-CD3 T3b. CD3 was cross-linked by using 10/zg/ml sheep anti-mouse IgG (XL-CD3). 
(B) T lymphoblasts were pretreated for 30 min at 4°C with a combination of either RPMI (e), HP2/19 (m), TP1/24 (*), or Lia 1/2 (v) 
mAbs with different doses of the anti-CD3 T3b mAb. Next,  10 #g/ml sheep anti-mouse IgG was added, as cross-linker, for 15 min at 
4°C. Adhesion to ICAM-1-Fc-coated (20 #g/ml) microtiter wells was quantified after 20 rain of incubation at 37°C. Specific adherence 
of stimulated T lymphoblasts was blocked by anti-LFA-I  t~ TPlt40 mAb (data not shown) which reduced adherence below the level of un- 
treated samples. Arithmetic mean and SD of duplicate wells are shown. Data are representative of six experiments. 
with the nonaggregatory anti-ICAM-3 TP1/24 mAb (Fig. 9 
A). As expected, cross-linked anti-CD3 mAb also enhanced 
cell adhesion to ICAM-1  (Fig. 9 A). Very interestingly, the 
anti-ICAM-3 HP2/19 but not the TP1/24 mAb was able to 
strongly enhance the LFA-l-mediated cell adhesion to ICAM- 
1-Fc when these stimuli were combined with very low doses 
of cross-linked anti-CD3 which were unable to'trigger cell 
adhesion by themselves (Fig. 9 B). Moreover, this effect was 
abolished when cells were simultaneously incubated in the 
presence of the TP1/24 mAb (data not shown). These results 
suggest  that  ICAM-3-induced  cell  aggregation  could  be 
mediated by increasing the affinity of LFA-1 for ICAM-1. 
Induction of CelIActivation through ICAM-3 
To further investigate the mechanism involved in the ICAM- 
3-mediated regulation of cell binding to ICAM-1,  we tested 
the possibility that cell activation could be achieved by mAb 
engagement  of ICAM-3.  As  shown  in  Fig.  10,  the  anti- 
ICAM-3 HP2/19 mAb (epitope A) was able to greatly stimu- 
late peripheral blood T cell proliferation when coimmobi- 
lized with suboptimal doses of the anti-CD3 T3b mAb. By 
contrast, the anti-HLA-A,B W6/32 mAb was not costimula- 
tory. These data indicate that ICAM-3 is able to mediate pe- 
ripheral blood T cell activation. 
Discussion 
In this report, we show that purified ICAM-3 can directly 
support LFA-l-depcndent lymphocyte adhesion. The results 
suggest that ICAM-3 has a role in the initial phases of leuko- 
cyte cell-cell contacts and that ICAM-3 is involved in the 
regulation of LFA-1/ICAM-l-dependent leukocyte intercellu- 
lar interactions. 
A previous report suggested that ICAM-3 could be a li- 
gand for LFA-1 supported by the fact that the anti-ICAM-3 
CBR-IC3/1  mAb was  able,  in conjunction with both anti- 
ICAM-1 and anti-ICAM-2 mAb, to block cell attachment to 
purified LFA-1 (De Fougerolles and Springer, 1992). Recent 
studies have shown that transfected cells with cDNAs encod- 
ing the ICAM-3 molecule were able to support leukocyte at- 
tachment  in  a  CDlla/CD18-dependent  manner  (De  Fou- 
gerolles et al.,  1993;  Fawcett et al.,  1992; Vazeux et al., 
1992). We demonstrate here that T lymphoblasts are able to 
bind directly to purified ICAM-3 through the LFA-1 integrin. 
Moreover, we have shown that LFA-l-dependent cell binding 
to purified ICAM-3 can be regulated either by cell activation 
(with phorbol esters or by cross-linking CD3-TcR) or by 
direct LFA-1 stimulation with the activating anti-LFA-1 NKI- 
L16 mAb.  Taking into account that anti-LFA-1  mAb com- 
pletely blocked cell adhesion to ICAM-3, it appears that ad- 
ditional receptors, besides LFA-1, are not involved. 
Epitope mapping on the ICAM-3 molecule revealed the 
existence of two distinct topographic epitopes, A and B, that 
showed distinct functional behavior, mAbs against epitope 
A,  but not those against epitope B,  induced a  very rapid 
aggregation of T  lymphoblasts that could be inhibited by 
anti-ICAM-3  (epitope B), anti-LFA-1,  and surprisingly, by 
anti-ICAM-1  mAbs. Immunofluorescence studies supported 
the involvement of LFA-1 and ICAM-I in ICAM-3-induced 
T  cell aggregation. Both ICAM-1  and activated LFA-1, but 
not ICAM-3, were almost exclusively localized in cell-cell 
boundaries.  Notably,  two different anti-LFA-1  mAbs  dis- 
played a very different pattern of cellular staining: NKI-L16 
mAb, recognizing an activation-related epitope on this inte- 
grin (Van Kooyk et al., 1991), was mainly located at intercel- 
lular contact sites,  whereas the regular anti-LFA-1  TS1/ll 
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Figure 10. ICAM-3-mediated enhancement of peripheral blood T 
cell proliferation. Flat-bottomed plates coated with F(ab% sheep 
anti-mouse IgG were incubated, as indicated under Materials and 
Methods, with 50 #1 anti-CD3 T3b mAb at 50 ng/ml plus either 
medium alone or 50 #1 at 2 #g/ml of each of the following mAb: 
anti-ICAM-3  HP2/19  and  TP1/24, and  anti-HLA-A,B  W6/32. 
Monocyte-depleted peripheral blood mononuclear ceils were cul- 
tured in these plates and proliferation was measured at day 3 by 
[3H]dThd uptake. When fiat-bottomed plates were coated in the 
absence of anti-CD3 mAb, [3H]dThd incorporation  was  always 
less than 6,000 cpm. Arithmetic mean and SD of triplicate wells 
are shown. Data are representative of four experiments. 
mAb, showed a diffuse pattern of staining. The presence of 
inductive and inhibitory sites for intercellular adhesion has 
been also described in members of the integrin superfamily 
of adhesion molecules such as LFA-lot (Keizer et al., 1988), 
VLA-ct4  (Campanero  et  al.,  1990),  and  VLA-/5'I (Cam- 
panero et al.,  1992). 
Since the inhibitory anti-ICAM-3 rnAb (epitope B) did not 
ablate mAb binding of proaggregatory (epitope A) mAb, nor 
blocked LFA-1 recognition of ICAM-3, we postulate that its 
inhibitory effect is due to interference with the mechanism 
of induction of cell aggregation by the anti-ICAM-3 HP2/19 
mAb.  In this regard,  we have observed that the increased 
LFA-l-mediated  cell  binding  to  ICAM-1  observed  upon 
cell treatment with the proaggregatory anti-ICAM-3 HP2/19 
mAb was blocked by anti-ICAM-3 mAb specific for epitope 
B. These results point to the possibility that enhancement of 
LFA-1 affinity for ICAM-1  could be one of the mechanisms 
of ICAM-3-mediated induction of cell aggregation. Likely, 
additional mechanisms could be acting; for instance, LFA-1/ 
ICAM-3 interaction promoted by treatment with the proag- 
gregatory  anti-ICAM-3  HP2/19  mAb  could  induce  the 
switch of LFA-1 to its activated state at the intercellular con- 
tact  sites.  Subsequently,  redistribution  of these  adhesion 
molecules on  the  cell  surface membrane  could  facilitate 
LFA-1 interaction with ICAM-1. 
Other functionally relevant cell surface molecules such as 
CD2, CD3, and CD1 la have been shown to enhance both ceil 
aggregation and LFA-l-mediated cell binding to ICAM-1 (Van 
Kooyk et al., 1989,  1991; Dustin and Springer, 1989). How- 
ever, this is the first evidence indicating that a counter-recep- 
tor for LFA-1 is able to mediate induction of LFA-l-mediated 
cell aggregation, as well as to increase the avidity of  this mol- 
ecule for a second counter-receptor, ICAM-1. In this regard, 
integrin activation by ligand, has been recently described for 
the  Ottrd33 integrin  (Du  et al.,  1991).  The mechanism  in- 
volved in ICAM-3-mediated regulation of LFA-1 avidity for 
ICAM-1  is presently unknown. However, we have obtained 
evidence suggesting that T cell activation could be involved 
in this process, since the proaggregatory anti-ICAM-3 HP2/ 
19 mAb was also costimulatory for peripheral blood T cells. 
We have shown that cell treatment with the anti-ICAM-3 
HP2/19 mAb induced changes in cell morphology, as well 
as relocation of the ICAM-3 molecule on the cell surface. 
Cells moved from rounded to elongated morphology, and an 
evident structure similar to an uropod, where ICAM-3 mole- 
cules were accumulated, was induced with this proaggrega- 
tory mAb.  Previous studies have shown that ICAM-1  can 
also preferentially localize to the uropod of both T and B cell 
lines (Dougherty et al.,  1988; Dustin et al.,  1992). 
A  striking difference in the distribution of the ICAM-3  ÷ 
uropod between  small  and large aggregates  was  seen.  In 
small aggregates, cells appear to contact each other through 
the uropods, whereas in large aggregates, uropods appear to 
be excluded from areas of cell-cell contact. Interestingly, 
cell boundaries were specifically stained by the anti-ICAM-1 
RR1/1 and the anti-LFA-1  NKI-L16 mAbs.  The location of 
the uropod and, therefore, that of ICAM-3, would be com- 
patible with its role as a mediator of the initial interactions 
between contacting leukocytes as well as in the recruitment 
of additional cells. 
Our data concerning the ability of ICAM-3  to support 
LFA-l-mediated cell attachment and to mediate induction of 
cell aggregation, confer to ICAM-3 a pivotal role in the regu- 
lation of  leukocyte intercellular interactions. It could be pos- 
tulated that a physiologic role for ICAM-3 during antigen- 
triggered intercellular lymphocyte interactions is to act as 
the first counter-receptor initiating the interaction with the 
preactivated LFA-1 integrin. The affinity of LFA-1 for ICAM-3 
could be lower than for ICAM-1, but, due to its much higher 
expression (De Fougerolles and Springer,  1992),  ICAM-3 
would be the initial counter-receptor for LFA-1. Accordingly, 
it has been shown that adhesion of resting T  lymphocytes 
to LFA-1 occurs primarily via ICAM-3 (De Fougerolles and 
Springer,  1992). In a second step, the initial interaction of 
ICAM-3 with LFA-1 on the opposite cell could increase the 
degree of activation of LFA-1 on both cells, thus facilitating 
the LFA-l-mediated cell binding to ICAM-1,  and the estab- 
lishment of  a more stable cell-cell interaction. In this regard, 
the existence of intermediate degrees of activation on the 
LFA-1 integrin has been previously reported (Van Kooyk et 
al., 1991). Later, ICAM-3 molecules would be displaced from 
sites of intercellular contact, thus becoming able to reinitiate 
additional interactions with other LFA-1 molecules on newly 
recruited cells. This putative role of ICAM-3 could be crucial 
during the initiation phase of important immune processes 
such as allogeneic and autologous mixed lymphocyte reac- 
tions and lysis by T cells of  certain target cells, which involve 
other LFA-1 ligands distinct from ICAM-1  (Bagnasco et al., 
1990;  Makgoba et al.,  1988). 
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